Telix Pharmaceuticals (TLX) Payables (2023 - 2025)

Telix Pharmaceuticals (TLX) has reported Payables for 3 consecutive years, with $163.5 million the latest figure, recorded in Q4 2025.

• Quarterly Payables rose 163.95% year-over-year to $163.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $163.5 million (up 163.95% YoY) and the FY2025 annual result came in at $163.5 million, up 163.95% from the prior year.
• Payables grew to $163.5 million in Q4 2025 per TLX's latest filing, from $61.9 million in the prior quarter.
• Over the last five years, Payables for TLX reached as high as $163.5 million in Q4 2025 and fell as low as $58.4 million in Q4 2023.
• A 3-year average of $94.6 million and a median of $61.9 million in 2024 frame the typical range for Payables.
• Annual changes were most pronounced in 2024 — Payables rose 6.07% — and 2025, when it soared 163.95%.
• Year by year, Payables stood at $58.4 million in 2023, then grew by 6.07% to $61.9 million in 2024, then soared by 163.95% to $163.5 million in 2025.
• According to Business Quant data, Payables over the past three periods registered $163.5 million, $61.9 million, and $58.4 million for Q4 2025, Q4 2024, and Q4 2023 respectively.